Is behavioural risk management the next frontier in clinical trials?

With the UK’s most significant clinical trial regulation update in over 20 years set for April 2026, risk management is taking on a new dimension. Regulators are pushing for a risk-proportionate approach that goes beyond traditional safety checks - now, participant behaviour and compliance are in the spotlight.

Why behavioural risk matters more than ever

• Regulatory emphasis on risk-proportionality

The updated regulations stress assessing both clinical and behavioural risks. It’s no longer enough to focus solely on adverse events.

• Streamlined safety reporting

Simplified reporting is designed to cut unnecessary duplication. Sponsors must now focus on meaningful risk mitigation strategies.

• Alignment with ICH E6(R3)

The new guideline encourages adaptive, risk-based trial designs where behavioural considerations are integrated into monitoring and quality planning.

Where behavioural risk shows up in trials

Behavioural risk affects trial quality, data integrity, and participant safety. Key areas include:

• Informed consent

Even simplified consent processes carry risk: ensuring participants truly understand the trial remains critical.

• Participant adherence

Deviations in taking medication, attending visits, or reporting side effects can undermine critical-to-quality factors.

• Protocol deviations

Non-compliance is often behaviour-driven. Anticipating and mitigating this risk is essential for maintaining study integrity.

• Data integrity

Participant behaviour can influence the reliability of collected data, potentially affecting study outcomes and regulatory acceptability.

Managing behavioural risk effectively

To mitigate these risks, trial teams should:

• Incorporate behavioural risk into trial design

Consider how participant behaviour could affect safety, adherence, and data quality.

• Develop monitoring strategies

Early identification of non-compliance or misunderstandings allows timely interventions.

• Train staff and investigators

Awareness of behavioural risk ensures everyone understands potential participant challenges.

• Engage participants proactively

Clear communication, reminders, and support systems reduce the likelihood of deviations and improve overall trial success.

Preparing for the regulatory shift

The April 2026 update is a call to action:

• Review risk-management frameworks to include behavioural factors.
• Ensure documentation reflects behavioural risk considerations throughout the trial lifecycle.
• Adopt adaptive monitoring techniques that capture behavioural trends and protocol adherence.
• Behavioural risk management is no longer optional. With regulatory guidance evolving, it’s becoming central to trial design, execution, and compliance. Trial teams that anticipate these challenges and integrate behavioural risk into their strategies will be better positioned to protect participants, maintain data quality, and stay ahead of regulatory expectations.

To discover more & get yourself fully prepared, join us on our course, Behavioural RIsk Management in Clinical Trials.

Published on Feb 18, 2026 by Simóne Blair